PharmiWeb.com - Global Pharma News & Resources
23-Jan-2019

CutisPharma Announces Launch of FIRST®-Metoprolol Unit-of-Use Prescription Compounding Kit for Oral Solution

WILMINGTON, Mass., Jan. 22, 2019 /PRNewswire/ -- CutisPharma, Inc. announced today the commercial availability of FIRST-Metoprolol grape-flavored oral solution compounding kit. FIRST-Metoprolol provides pharmacists with a convenient, high-quality, standardized way to compound an oral liquid metoprolol solution for patients who are not otherwise served by commercially available therapies, such as those who are unable to swallow solid oral dosing formulations.

"We are pleased to announce that, effective today, FIRST-Metoprolol is commercially accessible to all pharmacies in the United States," said Mike Radice, CutisPharma's Chief Commercial Officer. "The addition of FIRST-Metoprolol to our overall portfolio of FIRST Unit-of-Use Compounding Kits has been widely anticipated by our customers and will provide pharmacists with an expanded range of high-quality alternatives to traditionally compounded oral liquid suspensions and solutions."

FIRST-Metoprolol is now available in a 10 mg/mL strength in a convenient 300mL size. To allow additional flexibility for a variety of patient needs, an additional FIRST-Metoprolol 10 mg/mL 90mL size will be commercially available effective February 18, 2019. 

About CutisPharma

CutisPharma, Inc., based in Wilmington, MA, is a privately held, specialty pharmaceutical company that has been the industry leader for over 20 years in providing innovative solutions to pharmacists. CutisPharma's FIRST Unit-of-Use Compounding Kits have benefited millions of patients who are unable to swallow conventional oral dosage forms such as tablets and capsules and whose needs are not served by other commercially available therapies. In April 2018, CutisPharma announced the launch of FIRVANQ® (vancomycin hydrochloride for oral solution), the only FDA-approved vancomycin oral liquid therapy for patients with Clostridium difficile-associated diarrhea.  For more information, visit www.cutispharma.com, www.firvanq.com or contact us at media@cutispharma.com.

Editor Details

Related Links

Last Updated: 23-Jan-2019